Q4 2025 · 13F-HR
5AM Venture Management, LLCholdings as filed
Filed 2026-02-17 · accession 0001799883-26-000001
$318.1M
Reported value
21
Positions
2025-12-31
Period end
The Brief · 5AM Venture Management, LLC · Q4 2025
AI · grounded in 13F
5AM Venture Management, LLC closed its position in Dianthus Therapeutics Inc DNTH, reducing exposure by $14.36M. The fund established a new position in MapLight Therapeutics Inc MPLT valued at $16.69M. Additionally, the manager increased its stake in Zentalis Pharmaceuticals Inc ZNTL by 705.7% and exited its position in Praxis Precision Medicines I PRAX for $9.01M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $41.7M | 13.1% | 4,056,379 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $36.0M | 11.3% | 5,869,091 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $27.1M | 8.51% | 1,029,298 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $22.9M | 7.21% | 736,595 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $22.1M | 6.96% | 797,600 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $20.1M | 6.32% | 5,405,404 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT INC | $19.2M | 6.03% | 1,050,000 | Common | SOLE |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $16.7M | 5.25% | 950,011 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $14.5M | 4.57% | 580,945 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $13.5M | 4.25% | 497,270 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $12.7M | 3.98% | 606,660 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $11.9M | 3.74% | 772,477 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $10.1M | 3.17% | 2,353,304 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $8.8M | 2.75% | 387,500 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $8.3M | 2.62% | 738,972 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $7.3M | 2.30% | 1,369,782 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $7.3M | 2.29% | 572,665 | Common | SOLE |
| 83086J200 | SKYE | SKYE BIOSCIENCE INC | $7.3M | 2.28% | 9,681,763 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $5.3M | 1.68% | 3,947,913 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $2.9M | 0.91% | 476,200 | Common | SOLE |
| 75120L100 | RLYB | RALLYBIO CORP | $2.5M | 0.78% | 3,630,724 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.